Mayne Pharma Group Ltd (MYX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.086x

Based on the latest financial reports, Mayne Pharma Group Ltd (MYX) has a cash flow conversion efficiency ratio of 0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$31.98 Million ≈ $22.63 Million USD) by net assets (AU$370.28 Million ≈ $262.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Mayne Pharma Group Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Mayne Pharma Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MYX current and long-term liabilities for a breakdown of total debt and financial obligations.

Mayne Pharma Group Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mayne Pharma Group Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
BICO Group AB
ST:BICO
-0.017x
Clavister Holding AB (publ.)
ST:CLAV
-0.204x
Kao Fong Machinery Co Ltd
TWO:4510
-0.009x
Bank Capital Indonesia Tbk
JK:BACA
-0.012x
Ilyang Pharmaceutical Co Ltd
KO:007575
0.009x
UmweltBank AG
XETRA:UBK
-0.132x
Muhak Co. Ltd
KO:033920
-0.009x
Orogen Royalties Inc
V:OGN
0.015x

Annual Cash Flow Conversion Efficiency for Mayne Pharma Group Ltd (2007–2025)

The table below shows the annual cash flow conversion efficiency of Mayne Pharma Group Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see MYX market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$370.28 Million
≈ $262.00 Million
AU$17.47 Million
≈ $12.36 Million
0.047x +240.05%
2024-06-30 AU$454.19 Million
≈ $321.37 Million
AU$-15.30 Million
≈ $-10.83 Million
-0.034x +49.97%
2023-06-30 AU$634.36 Million
≈ $448.85 Million
AU$-42.71 Million
≈ $-30.22 Million
-0.067x -420.56%
2022-06-30 AU$557.12 Million
≈ $394.20 Million
AU$-7.21 Million
≈ $-5.10 Million
-0.013x -121.12%
2021-06-30 AU$771.58 Million
≈ $545.94 Million
AU$47.26 Million
≈ $33.44 Million
0.061x -36.02%
2020-06-30 AU$1.04 Billion
≈ $737.50 Million
AU$99.78 Million
≈ $70.60 Million
0.096x -8.94%
2019-06-30 AU$1.01 Billion
≈ $717.52 Million
AU$106.61 Million
≈ $75.43 Million
0.105x +6.87%
2018-06-30 AU$1.24 Billion
≈ $873.95 Million
AU$121.50 Million
≈ $85.97 Million
0.098x +947.27%
2017-06-30 AU$1.31 Billion
≈ $928.62 Million
AU$-15.24 Million
≈ $-10.78 Million
-0.012x -108.16%
2016-06-30 AU$376.22 Million
≈ $266.20 Million
AU$53.50 Million
≈ $37.86 Million
0.142x +104.38%
2015-06-30 AU$322.20 Million
≈ $227.98 Million
AU$22.42 Million
≈ $15.86 Million
0.070x -57.60%
2014-06-30 AU$159.27 Million
≈ $112.70 Million
AU$26.14 Million
≈ $18.49 Million
0.164x +189.81%
2013-06-30 AU$120.89 Million
≈ $85.54 Million
AU$6.84 Million
≈ $4.84 Million
0.057x -87.06%
2012-06-30 AU$30.60 Million
≈ $21.65 Million
AU$13.39 Million
≈ $9.47 Million
0.437x +158.83%
2011-06-30 AU$24.17 Million
≈ $17.10 Million
AU$4.09 Million
≈ $2.89 Million
0.169x -57.89%
2010-06-30 AU$25.55 Million
≈ $18.08 Million
AU$10.26 Million
≈ $7.26 Million
0.401x +186.15%
2009-06-30 AU$7.70 Million
≈ $5.45 Million
AU$-3.59 Million
≈ $-2.54 Million
-0.466x -76.14%
2008-06-30 AU$11.44 Million
≈ $8.09 Million
AU$-3.03 Million
≈ $-2.14 Million
-0.265x -209.97%
2007-06-30 AU$14.51 Million
≈ $10.27 Million
AU$-1.24 Million
≈ $-876.47K
-0.085x --

About Mayne Pharma Group Ltd

AU:MYX Australia Medical Distribution
Market Cap
$159.81 Million
AU$225.86 Million AUD
Market Cap Rank
#17374 Global
#518 in Australia
Share Price
AU$2.78
Change (1 day)
-2.11%
52-Week Range
AU$2.13 - AU$7.12
All Time High
AU$41.75
About

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more